

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number
WO 2004/094420 A1

(51) International Patent Classification⁷: **C07D 471/04**,
487/04

(21) International Application Number:
PCT/IB2004/001350

(22) International Filing Date: 7 April 2004 (07.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0308208.8 9 April 2003 (09.04.2003) GB
60/485,322 7 July 2003 (07.07.2003) US

(71) Applicants (for all designated States except US): **SB PHARMCO PUERTO RICO INC** [US/US]; CSC The United States Corporation Company, 105 Ponce de Leon Avenue, One Comptroller Plaza, Hato Rey, Puerto Rico, 00917 (US). **NEUROCRINE BIOSCIENCES INC** [US/US]; 10555 Science Center Drive, San Diego, California 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANDREOTTI, Daniele** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **BERNASCONI, Giovanni** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **CASTIGLIONI, Emiliano** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **CONTINI, Stefania** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **DI FABIO, Romano** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **FAZZOLARI, Elettra** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **FERIANI, Aldo** [IT/IT]; GlaxoSmithKline

SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **GENTILE, Gabriella** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **MATTIOLI, Mario** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **MINGARDI, Anna** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **SABBATINI, Fabio** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **ST-DENIS, Yves** [CA/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT).

(74) Agent: **GIDDINGS, Peter John**; GlaxoSmithKline, Corporate Intellectual Property, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS



(I)

(57) Abstract: The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof (Formula (I)) wherein the dashed line may represent a double bond; R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from: halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 lkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, -C(O)R₂, nitro, hydroxy, -NR₃R₄, cyano and or a group Z; R₁ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR₃R₄ or cyano; D, G is -C- optionally substituted; X is carbon or nitrogen; Y is nitrogen or -C- optionally substituted; W is a 4-8 membered ring, which may be saturated or may

contain one to three double bonds, and in which: - one carbon atom is replaced by a carbonyl or S(O)_m; and - one to four carbon atoms may optionally be replaced by oxygen, nitrogen or NR₁₂, S(O)_m, carbonyl, and such ring may be further substituted by 1 to 8 substituents; Z is a 5-6 membered heterocycle, which may be substituted by 1 to 8 R₅ groups or a phenyl ring, which may be substituted by 1 to 4 substituents; m is an integer from 0 to 2. to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).



— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.